Kiadis Pharma NV launched a private placement of about 2.6 million new shares to institutional investors.
The share sales represent about 14.8% of the Amsterdam-based company's current issued share capital.
The developer of therapies for blood disorders will announce the number of shares placed and the subscription price for the placing on March 13.
Kiadis Pharma intends to use the net proceeds of the placing to fund the development of its blood cancer drug ATIR101 as well as for expenses and general corporate purposes.
Jefferies International Ltd. is acting as sole book runner, Canaccord Genuity Ltd. as lead manager, Chardan as co-lead manager and LifeSci Capital LLC as co-manager in connection with the placement.
Saola Healthcare Partners is acting as financial adviser to the company.
